Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address chemotherapy resistance and cumulative toxicity. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in this setting, and concurrent immune checkpoint blockade c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2022-08, Vol.23 (8), p.1009-1020
Hauptverfasser:	Reiss, Kim A, Mick, Rosemarie, Teitelbaum, Ursina, O'Hara, Mark, Schneider, Charles, Massa, Ryan, Karasic, Thomas, Tondon, Rashmi, Onyiah, Chioma, Gosselin, Mary Kate, Donze, Alyssa, Domchek, Susan M, Vonderheide, Robert H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Anemia Antineoplastic Combined Chemotherapy Protocols - adverse effects Cancer therapies Chemoresistance Chemotherapy Clinical trials CTLA-4 protein Cytotoxicity DNA damage Drug dosages FDA approval Humans Hypertension Hypertension - chemically induced Immune checkpoint Immune Checkpoint Inhibitors Immunotherapy Indazoles Ipilimumab Metastasis Monoclonal antibodies Neutropenia Nivolumab - adverse effects Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Patients PD-1 protein Piperidines Platinum Poly(ADP-ribose) Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - adverse effects Review boards Ribose Safety Solid tumors Survival Targeted cancer therapy Thrombocytopenia Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!